{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:31:28Z","timestamp":1793943088772,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-024-05117-5","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T12:02:59Z","timestamp":1730116979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-4890","authenticated-orcid":false,"given":"Patrick M.","family":"Honor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-0829","authenticated-orcid":false,"given":"Massimo","family":"Girardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-5877","authenticated-orcid":false,"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-8167","authenticated-orcid":false,"given":"Bart Jan","family":"Kullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9325-0323","authenticated-orcid":false,"given":"Nick","family":"Manamley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0357","authenticated-orcid":false,"given":"Saad","family":"Nseir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"5117_CR1","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"5117_CR2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","volume":"46","author":"C Logan","year":"2020","unstructured":"Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med. 2020;46(11):2001\u201314.","journal-title":"Intensive Care Med"},{"issue":"Suppl 7","key":"5117_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5117_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5117_CR5","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","volume":"49","author":"M Morrell","year":"2005","unstructured":"Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"5117_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/cid\/cis305","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739\u201346.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5117_CR7","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","volume":"4","author":"F Daneshnia","year":"2023","unstructured":"Daneshnia F, de Almeida Junior JN, Ilkit M, Lombardi L, Perry AM, Gao M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023;4(6):e470\u201380.","journal-title":"Lancet Microbe"},{"issue":"8","key":"5117_CR8","doi-asserted-by":"publisher","first-page":"e00591","DOI":"10.1128\/AAC.00591-18","volume":"62","author":"B Goemaere","year":"2018","unstructured":"Goemaere B, Lagrou K, Spriet I, Hendrickx M, Becker P. Clonal spread of Candida glabrata bloodstream isolates and fluconazole resistance affected by prolonged exposure: a 12-year single-center study in Belgium. Antimicrob Agents Chemother. 2018;62(8):e00591-e618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5117_CR9","first-page":"831","volume":"73","author":"JC Bader","year":"2018","unstructured":"Bader JC, Bhavnani SM, Andes DR, Ambrose PG. We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother. 2018;73(3):831.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"5117_CR10","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson III","year":"2021","unstructured":"Thompson GR III, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73(11):e3647\u201355.","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"5117_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson III","year":"2023","unstructured":"Thompson GR III, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49\u201359.","journal-title":"Lancet"},{"key":"5117_CR12","unstructured":"Clinical Trials.gov. Study of rezafungin compared to standard antimicrobial regimen for prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation (ReSPECT) [NCT04368559]. 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04368559. Accessed 26 June 2023."},{"issue":"2","key":"5117_CR13","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","volume":"61","author":"T Sandison","year":"2017","unstructured":"Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2):e01627-e1716.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5117_CR14","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/cmi.12640","volume":"18","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Perez WB, Jim\u00e9nez-Ortigosa C, Hough G, Locke JB, Ong V, et al. CD101: a novel long-acting echinocandin. Cell Microbiol. 2016;18(9):1308\u201316.","journal-title":"Cell Microbiol"},{"issue":"6","key":"5117_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/jac\/dkq081","volume":"65","author":"MW Pound","year":"2010","unstructured":"Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother. 2010;65(6):1108\u201318.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"5117_CR16","doi-asserted-by":"publisher","first-page":"e01009","DOI":"10.1128\/AAC.01009-17","volume":"61","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen PY, Blanc L, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61(10):e01009-e1017.","journal-title":"Antimicrob Agents Chemother"},{"key":"5117_CR17","unstructured":"Gallagher A. FDA approves rezafungin injection for the treatment of candidemia, invasive candidiasis. 2023. https:\/\/www.pharmacytimes.com\/view\/fda-approves-rezafungin-injection-for-the-treatment-of-candidemia-invasive-candidiasis. Accessed 1 Jun 2023."},{"key":"5117_CR18","unstructured":"European Medicines Agency. Rezzayo (rezafungin) Summary of Product Characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezzayo-epar-product-information_en.pdf. Accessed 1 Feb 2024."},{"key":"5117_CR19","unstructured":"Mundipharma. Press release: European approval of REZZAYO\u00ae (rezafungin) for the treatment of Invasive Candidiasis in adults. 2023. https:\/\/www.mundipharma.com\/mundipharma-announces-european-approval-of-rezzayo. Accessed 2 Jan 2024."},{"issue":"3","key":"5117_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","volume":"24","author":"GR Thompson III","year":"2024","unstructured":"Thompson GR III, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, et al. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Infect Dis. 2024;24(3):319\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5117_CR21","doi-asserted-by":"crossref","first-page":"e01582","DOI":"10.1128\/AAC.01582-16","volume":"61","author":"KC van der Elst","year":"2017","unstructured":"van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, et al. Low caspofungin exposure in patients in intensive care units. Antimicrob Agents Chemother. 2017;61(2):e01582-e1616.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"5117_CR22","doi-asserted-by":"publisher","first-page":"e01398","DOI":"10.1128\/AAC.01398-17","volume":"61","author":"JM Boonstra","year":"2017","unstructured":"Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Br\u00fcggemann RJ, Koster RA, et al. Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother. 2017;61(12):e01398-e1417.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_1","key":"5117_CR23","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/jac\/dkx447","volume":"73","author":"F Pea","year":"2018","unstructured":"Pea F, Lewis RE. Overview of antifungal dosing in invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i33\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"5117_CR24","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1128\/AAC.00620-16","volume":"60","author":"JB Locke","year":"2016","unstructured":"Locke JB, Almaguer AL, Zuill DE, Bartizal K. Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother. 2016;60(10):6100\u20137.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-05117-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:40:04Z","timestamp":1751611204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-05117-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5117"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-05117-5","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"STRIVE and ReSTORE were conducted in accordance with current regulations, the International Conference on Harmonisation Good Clinical Practice, and the Declaration of Helsinki. Ethics committees or institutional review boards at participating sites approved the protocol and all amendments. All patients, or their legally authorised representatives, provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PMH reports grants or contracts from Baxter, Cytosorbents, and Pfizer; consulting fees from Baxter, Cytosorbents, and Pfizer; honoraria from Baxter, and Cytosorbents; and support for attending meetings from Mundipharma, and Pfizer, outside of the submitted work. MG reports consulting fees and\/or payment for speaking for Biotest, Pfizer, MSD, Gilead, Estor, Viatris, AOP Pharma, Fresenius, and Orion. MK reports funding from the Barnes-Jewish Hospital Foundation. OAC reports grants or contracts from BMBF, Cidara, EU-DG RTD (101037867), F2G, Gilead, Medpace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from AbbVie, AiCuris, Biocon, Cidara, Gilead, IQVIA, Janssen, Matinas, Medpace, Menarini, Moderna, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pfizer, PSI, Scynexis, and Seres; honoraria for lectures from Abbott, AbbVie, Al-Jazeera Pharmaceuticals\/Hikma, Gilead, Grupo Biotoscana\/United Medical\/Knight, Medscape, MedUpdate, Merck\/MSD, Noscendo, Pfizer, Shionogi, and streamedup!; payment for expert testimony from Cidara; participation on a data safety monitoring board or advisory board from Boston Strategic Partners, Cidara, IQVIA, Janssen, Medpace, PSI, Pulmocide, Shionogi, and the Prime Meridian Group; and has stocks or stock options in CoRe Consulting and EasyRadiology. GRT reports grants and consulting fees from Amplyx, Astellas, Cidara, F2G, and Manye; grants from Merck; and data safety monitoring board membership for Pfizer. MB reports consulting fees and payment or honoraria for lectures, presentations, speaker bureaux, manuscript writing, or educational events from MSD, Pfizer, Menarini, Shionogi, Angelini, and Gilead; and data safety monitoring board or advisory board participation for Cidara and Mundipharma. AS reports grants from Pfizer and Gilead Sciences; and honoraria for lectures and advisory boards from Pfizer, MSD, Shionogi, Angelini, and Menarini. HH reports no conflicts of interest. JV reports grants from Cidara, F2G, Scynexis, and Amplyx; consulting fees from Cidara and F2G; payment or honoraria for lectures, presentations, speaker bureaux, manuscript writing, or educational events from Melinta; and data safety monitoring board or advisory board participation for F2G. BJK served on the independent data review committee for Cidara. PGP reports grants from and data review committee membership for Cidara and Melinta; grants from Astellas, Scynexis, and Merck; consulting fees from Cidara and Melinta; and advisory board membership for F2G, Matinas and TFF Pharma. NM is an employee of Mundipharma Research Ltd. TS is an employee and shareholder of Cidara Therapeutics. JP reports no conflicts of interest. SN reports honoraria for lectures and advisory boards from Pfizer, MSD, bioM\u00e9rieux, Fisher and Paykel, Mundipharma, and Medtronic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}